Navigation Links
Herceptin May Boost Long-Term Survival After Aggressive Breast Cancer
Date:2/25/2011

By Maureen Salamon
HealthDay Reporter

THURSDAY, Feb. 24 (HealthDay News) -- The cancer drug Herceptin produces significantly longer disease-free survival in women with an aggressive type of early-stage breast cancer who take the drug for a year after standard chemotherapy, a new study suggests.

After analyzing more than 5,000 women from 39 countries between December 2001 and June 2005, Herceptin appeared to reduce the likelihood of a cancer recurrence by 24 percent, the Italian researchers said.

Herceptin (trastuzumab) is a monoclonal antibody that suppresses the HER2/neu protein, which fuels 20 percent to 30 percent of breast cancers. These so-called HER2-positive cancers tend to be aggressive and fast-growing.

"We were inclined to consider the possibility that long-term exposure to trastuzumab deserved a proper test and might be useful," said study author Dr. Luca Gianni, a researcher at Fondazione San Raffaele in Milan.

But while Herceptin patients in the four-year study experienced longer disease-free survival times than patients in an observation group taking chemotherapy alone, the overall risk of death was similar between the two groups.

Gianni attributed this to the fact that 52 percent of patients from the observation group crossed over to receive Herceptin treatment midway through the research because of the drug's impressive early results.

The study received funding from Hoffman-La Roche, the maker of Herceptin, and is published in the Feb. 25 issue of The Lancet Oncology.

"It is very difficult to account for the bias introduced by the late introduction of trastuzumab in more than half of the patients originally randomized to no therapy," Gianni said. "However, it is reasonable to think that the lack of a measurable improvement of survival in the current analysis was due to the effect of the introduction of trastuzumab therapy in a large proportion of women who selecte
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved  

0

GOOD

Page: 1 2 3

Related medicine news :

1. Herceptin and Tykerb effective against a subset of gastric cancers
2. Roche/Genentech/Chugais Herceptin as an Add-On to Standard Chemotherapy Will Become Decision Resources Clinical Gold Standard in 2013 for the Treatment Of Gastric Cancer
3. MiRNA-21 linked to tumor suppressor loss, herceptin resistance
4. Drug now used to treat erectile dysfuncton may enhance delivery of herceptin to certain brain tumors
5. Erythropoietin counteracts breast cancer treatment with herceptin
6. Global Nutrition Firm Takes Dose of SonicWALL to Boost Network Health
7. Aspirin May Boost Breast Cancer Survival
8. A midday nap markedly boosts the brains learning capacity
9. CustomerCentric Selling Helps BCC Software Dramatically Boost Sales Performance and Produce Record Results
10. Dry Weather Boosts Odds of Flu Outbreaks
11. Fitness Boosts Brain Power in Multiple Sclerosis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Herceptin May Boost Long-Term Survival After Aggressive Breast Cancer
(Date:5/22/2013)... (PRWEB) May 22, 2013 According to a ... “Women Have More Options for Breast Cancer Surgery,” modern medical ... opportunity to approach this disease in a whole new light. ... developed, women now face breast cancer and mastectomies ... goo.gl/ARqoN). , “Before the introduction of plastic surgery to oncology, ...
(Date:5/22/2013)... genomic health disparities from the University of Miami Miller ... Medicine have teamed up to hold the second annual ... in Genomic Medicine." The theme of this year,s ... government to reduce these disparities. , Despite steady improvement ... within underserved groups continue to be more vulnerable to ...
(Date:5/22/2013)... 22, 2013 Award Presented at the ... press release here: http://bit.ly/13DkFfk , Merrill Corporation ... “Information Management Product/Service of the Year” at the 7th ... The Colony Hotel in Palm Beach, Florida. , ... room (VDR) solution that optimizes the due diligence ...
(Date:5/22/2013)... May 22, 2013 Registered Dietitian and Founder ... today on Tatalou.com sharing a recipe for making energy bars ... Healthy Energy Bars ,” takes a recipe modified from one ... twists. , “Every day it gets more and more difficult ... said Chevreau. “The size of the nutrition label continues to ...
(Date:5/22/2013)... 2013 Pamela Isom, President and CEO ... Business Journal’s 2013 Women of Influence Award in recognition ... , The reception took place on Thursday, May 2 ... Influence is particularly humbling for the 5,000 people ICE ... success is to recognize the four to nine lives ...
Breaking Medicine News(10 mins):Health News:Breast Augmentation – New Option for Breast Cancer Surgeries 2Health News:Why We Can't Wait: Conference to Eliminate Health Disparities in Genomic Medicine 2Health News:Merrill DataSite New Press Release: Merrill DataSite® Virtual Data Room Honored as “Information Management Product/Service of the Year” 2Health News:Merrill DataSite New Press Release: Merrill DataSite® Virtual Data Room Honored as “Information Management Product/Service of the Year” 3Health News:How To "Make Your Own Healthy Energy Bars" 2Health News:Pamela Isom, President and CEO of ICE Safety Solutions Inc. Receives 2013 Women of Influence Recognition and Award 2
... (HealthDay News) -- Teens undergoing treatment for alcohol or ... by groups such as Alcoholics Anonymous (AA) and Narcotics ... widely available, little research has looked at how effective ... 127 teen substance abuse-treatment outpatients (95 males, 32 females, ...
... April 16 (HealthDay News) -- Surgery for non-melanoma skin cancer ... mainly due to the increased use of a specific surgical ... in the outer layer of the skin or in skin ... according to the U.S. National Cancer Institute. More than ...
... Reinberg HealthDay Reporter , MONDAY, April 16 (HealthDay ... in the brains of people with multiple sclerosis (MS), researchers ... ONO-4641, "actually caused a reduction in relapses, which is somewhat ... said lead researcher Dr. Timothy Vollmer, a professor of neurology ...
... HealthDay Reporter , MONDAY, April 16 (HealthDay News) -- In a ... participated in the "choking game," in which blood and oxygen to ... produce a euphoric "high." What,s more, the researchers found that ... and many practiced other risky behaviors. "If kids do participate, ...
... Early symptoms of major mental illness can be ... be missed, or even ignored due to conventional wisdom ... deterioration and prolonged patterns of abnormality before diagnosing and ... waiting until someone is so ill that the psychological ...
... thought to play a crucial role in regulating cell proliferation. ... and interact with one another in intact animals., This study ... functional placenta and for balancing the effect of an E2F ... genes in a family of regulatory genes are vital for ...
Cached Medicine News:Health News:12-Step Meetings May Help Teens Beat Alcohol, Drug Abuse 2Health News:Surgery Rates Rising for Non-Melanoma Skin Cancer: Study 2Health News:Experimental Pill for Multiple Sclerosis Shows Promise 2Health News:Experimental Pill for Multiple Sclerosis Shows Promise 3Health News:Young Risk-Takers Drawn to Dangerous 'Choking Game' 2Health News:Young Risk-Takers Drawn to Dangerous 'Choking Game' 3Health News:First contact: Early intervention key in diagnosis and treatment of serious mental illness 2Health News:2 repressor genes identified as essential for placental development 2
(Date:5/22/2013)... TORONTO , May 22, 2013 /PRNewswire/ ... announced three presentations demonstrating the superiority of the AE37 ... Antigen Express, Inc. ( www.antigenexpress.com ). The presentations will ... Society of Clinical Oncology (ASCO) to be held in ... June 4, 2013. The presentation entitled " ...
(Date:5/22/2013)... , 22. Mai 2013  Grifols, ein ... Barcelona , Spanien, präsentierte ... eine höhere Dosis von PROLASTIN©-C (Alpha1-Proteinasehemmer [human]) ... Alpha1-Antitrypsinmangel (AAT) auf ein Niveau anhebt, das ... Bereichs liegt. ATT-Mangel ist eine lebensbedrohliche, genetische ...
(Date:5/22/2013)... , May 22, 2013  Medifocus, Inc. (OTCQX: MDFZF and ... , Chief Operating Officer, will present at the Second Annual ... New York City at the Grand ... to begin at 4:00 p.m. EDT and will be available ...   http://wsw.com/webcast/marcum/mfs.v/   For more information and registration, ...
Breaking Medicine Technology:Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 2Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 3Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 4Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 2Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 3Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 4Medifocus, Inc. to Present At The Second Annual Marcum LLP MicroCap Conference 2Medifocus, Inc. to Present At The Second Annual Marcum LLP MicroCap Conference 3
... 48-week investigational regimen yielded nearly double SVR rate ... protease inhibitor SCH 900518 presented at EASL annual ... SGP ) today reported that final ... its investigational oral hepatitis C protease inhibitor, in ...
... Potential of Fully Human Anti-PS Antibodies and ... Equivalent to the Human Antibody Inhibited Tumor ... More than 90%-DENVER and TUSTIN, Calif., April ... PPHM), a clinical stage biopharmaceutical company ...
Cached Medicine Technology:Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 2Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 3Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 4Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 5Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 6Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 7Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 8Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 9Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 10Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 11Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 12Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrine's Fully Human Anti-PS Antibody in Prostate Cancer Model 2Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrine's Fully Human Anti-PS Antibody in Prostate Cancer Model 3Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrine's Fully Human Anti-PS Antibody in Prostate Cancer Model 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: